At Kayentis, we are proud to share the results of our latest client survey, conducted in January 2026. This year’s feedback confirms what drives us every day: a commitment to excellence, trusted partnerships, and continuous innovation to support increasingly complex clinical trials.
With even stronger results than last year, our clients’ feedback reinforces the solid trust and confidence they consistently place in our team, our product, and our long-term vision.
95.9% Recommendation Rate, marking 5 consecutive years above 90%
We are delighted to announce that 95.9% of our clients would recommend Kayentis to a colleague or partner. This marks the fifth consecutive year we have achieved a recommendation rate above 90%: a milestone that reflects both sustained excellence and the strength of the long-term relationships we build with our clients.
Such consistency is only possible thanks to trusted partnerships, high standards, and a continuous commitment to improvement.
Clients consistently describe our teams as collaborative and responsive, highlighting the ease of communication and our ability to adapt quickly to evolving needs:
“The team has been consistently professional and a pleasure to work with. They are collaborative, responsive, and genuinely invested in partnership.“
Net Promoter Score of +72
Our Net Promoter Score has also increased to +72, further exceeding industry benchmarks. This significant improvement also reflects the strong trust our clients place in us and their willingness to actively advocate for our partnership. They value the structured, transparent way we manage projects and ensure compliance, providing reassurance at every stage of their clinical trials.
Clients emphasize not only our expertise, but also the strength and reliability of our product, supported by a clear and forward-looking roadmap:
“Their product offering is strong and well thought out, supported by solid governance and clear processes. Importantly, they listen carefully to our needs and demonstrate flexibility by adapting their approach when appropriate.“
Strong innovation, and long-term value creation
Beyond performance metrics, this year’s feedback highlights a key topic: the recognition of our strong commitment to innovation in complex trial management.
Our clients recognize our clear roadmap for innovation, demonstrating our commitment to continuous improvement and long-term value creation.
“They are excellent partners, with great communication, roadmap/innovation, and the willingness to collaborate on path forward improvement. I encourage them to continue being an excellent, reliable partner and leader in the industry.”
All these insights reinforce our ambition to remain a trusted and innovative partner, one that combines operational excellence, strategic vision, and a collaborative mindset. As we move forward, our focus remains clear: to deliver excellence, foster strong governance, drive innovation, and build lasting partnerships that support the success of every clinical trial we contribute to.
